SiRNA-based topical microbicides targeting sexually transmitted infections

Joseph A. Katakowski, Deborah Palliser

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Sexually transmitted infections (STIs) are a major cause of morbidity and mortality worldwide. Although a vaccine is available for HPV, no effective vaccines exist for the HIV-1 and HSV-2 viral pathogens, and there are no cures for these infections. Furthermore, recent setbacks in clinical trials, such as the failure of the STEP trial to prevent HIV-1 infection, have emphasized the need to develop alternative approaches to interrupt the transmission of these pathogens. One alternative strategy is represented by the use of topically applied microbicides, and such agents are being developed against various viruses. RNAi-based microbicides have recently been demonstrated to prevent HSV-2 transmission, and may be useful for targeting multiple STIs. In this review, microbicides that are under development for the prevention of STIs are described, with a focus on topically applied microbicidal siRNAs.

Original languageEnglish (US)
Pages (from-to)192-202
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume12
Issue number2
StatePublished - Apr 2010

Fingerprint

Local Anti-Infective Agents
Sexually Transmitted Diseases
Anti-Infective Agents
Human Herpesvirus 2
HIV-1
Vaccines
Infectious Disease Transmission
RNA Interference
HIV Infections
Clinical Trials
Viruses
Morbidity
Mortality
Infection

Keywords

  • HIV-1
  • HSV-2
  • Microbicide
  • RNAi
  • Sexually transmitted infection
  • Targeted therapy

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery
  • Pharmacology

Cite this

SiRNA-based topical microbicides targeting sexually transmitted infections. / Katakowski, Joseph A.; Palliser, Deborah.

In: Current Opinion in Molecular Therapeutics, Vol. 12, No. 2, 04.2010, p. 192-202.

Research output: Contribution to journalArticle

Katakowski, Joseph A. ; Palliser, Deborah. / SiRNA-based topical microbicides targeting sexually transmitted infections. In: Current Opinion in Molecular Therapeutics. 2010 ; Vol. 12, No. 2. pp. 192-202.
@article{ef4524351e4e4447b7aff0b205b36f41,
title = "SiRNA-based topical microbicides targeting sexually transmitted infections",
abstract = "Sexually transmitted infections (STIs) are a major cause of morbidity and mortality worldwide. Although a vaccine is available for HPV, no effective vaccines exist for the HIV-1 and HSV-2 viral pathogens, and there are no cures for these infections. Furthermore, recent setbacks in clinical trials, such as the failure of the STEP trial to prevent HIV-1 infection, have emphasized the need to develop alternative approaches to interrupt the transmission of these pathogens. One alternative strategy is represented by the use of topically applied microbicides, and such agents are being developed against various viruses. RNAi-based microbicides have recently been demonstrated to prevent HSV-2 transmission, and may be useful for targeting multiple STIs. In this review, microbicides that are under development for the prevention of STIs are described, with a focus on topically applied microbicidal siRNAs.",
keywords = "HIV-1, HSV-2, Microbicide, RNAi, Sexually transmitted infection, Targeted therapy",
author = "Katakowski, {Joseph A.} and Deborah Palliser",
year = "2010",
month = "4",
language = "English (US)",
volume = "12",
pages = "192--202",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - SiRNA-based topical microbicides targeting sexually transmitted infections

AU - Katakowski, Joseph A.

AU - Palliser, Deborah

PY - 2010/4

Y1 - 2010/4

N2 - Sexually transmitted infections (STIs) are a major cause of morbidity and mortality worldwide. Although a vaccine is available for HPV, no effective vaccines exist for the HIV-1 and HSV-2 viral pathogens, and there are no cures for these infections. Furthermore, recent setbacks in clinical trials, such as the failure of the STEP trial to prevent HIV-1 infection, have emphasized the need to develop alternative approaches to interrupt the transmission of these pathogens. One alternative strategy is represented by the use of topically applied microbicides, and such agents are being developed against various viruses. RNAi-based microbicides have recently been demonstrated to prevent HSV-2 transmission, and may be useful for targeting multiple STIs. In this review, microbicides that are under development for the prevention of STIs are described, with a focus on topically applied microbicidal siRNAs.

AB - Sexually transmitted infections (STIs) are a major cause of morbidity and mortality worldwide. Although a vaccine is available for HPV, no effective vaccines exist for the HIV-1 and HSV-2 viral pathogens, and there are no cures for these infections. Furthermore, recent setbacks in clinical trials, such as the failure of the STEP trial to prevent HIV-1 infection, have emphasized the need to develop alternative approaches to interrupt the transmission of these pathogens. One alternative strategy is represented by the use of topically applied microbicides, and such agents are being developed against various viruses. RNAi-based microbicides have recently been demonstrated to prevent HSV-2 transmission, and may be useful for targeting multiple STIs. In this review, microbicides that are under development for the prevention of STIs are described, with a focus on topically applied microbicidal siRNAs.

KW - HIV-1

KW - HSV-2

KW - Microbicide

KW - RNAi

KW - Sexually transmitted infection

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77950826873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950826873&partnerID=8YFLogxK

M3 - Article

C2 - 20373263

AN - SCOPUS:77950826873

VL - 12

SP - 192

EP - 202

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 2

ER -